Carlos Telleria
BSc, PhD
Dr. Carlos Telleria received his doctoral training from the National Council for Scientific and Technical Research (Conicet) of Argentina, and acquired postdoctoral expertise at the Department of Physiology, College of Medicine of the University of Illinois at Chicago. Before joining the Department of Pathology at 污污草莓视频 University, Dr. Telleria navigated the academic ranks at the Division of Biomedical Sciences of the Sanford School of Medicine of the University of South Dakota. During his years as an academic researcher, Dr. Telleria mentored several undergraduate and graduate students and received various awards for research and teaching excellence. Dr. Telleria is currently a member of the editorial board of various peer reviewed scientific journals, including Hormones and Cancer, Scientific Reports, Biology of Reproduction, Reproductive Biology and Endocrinology, and Cancer Growth and Metastasis.
My research focuses on studying ovarian cancer, which is the most lethal gynecological malignancy. Although diagnosis is often reached when the disease is highly advanced, 70% of patients respond to surgery and platinum-based therapy with remission. Unfortunately, the disease usually recurs with a platinum-resistant phenotype leading to a 5-year survival below 40%. Thus, innovative therapies for usage after standard of care are urgently needed. The overall therapeutic approach followed in my laboratory is to consider that the time between remission and recurrence can be exploited by using a chronic intervention to maintain residual ovarian cancer cells, which had escaped initial therapy, in a non-proliferative or 鈥渄ormant鈥� status. Within this scope, current investigations are tailored to understand the pathobiology of ovarian cancer within the microenvironment of the peritoneal cavity, to study the molecular mechanisms driving dormancy of cancer cells that had survived chemotherapy, and to exploit protein homeostasis and oxidative stress to develop therapies for non-dividing cancer cells.